Colorectal AdenomaColorectal Cancer Precancerous Lesion
Study summary
This study aims to explore epigenetic factors associated with colorectal adenoma (CRA) in the Korean population. CRA is a key precancerous lesion in the adenoma-carcinoma sequence, and identifying methylated genetic markers may improve early detection and risk stratification for colorectal cancer (CRC).
A total of 32 patients undergoing colonoscopic polypectomy will be enrolled. Adenomatous and adjacent normal tissues will be collected for deoxyribonucleic acid (DNA) extraction and bisulfite conversion. Quantitative methylation-specific polymerase chain reaction (qMSP) and Sanger sequencing will be used to assess the methylation status of candidate genes (SFRP2, TFPI2, SEPT9, and SDC2). Stool samples will also be analyzed by whole-genome sequencing (WGS) to evaluate microbiome and genetic profiles.
The study seeks to determine whether methylation levels of these genes are significantly elevated in adenoma tissue compared with normal mucosa, thereby identifying potential biomarkers for colorectal neoplasia surveillance and personalized colonoscopy follow-up intervals.
Eligibility
Sex
ALL
Min age
19 Years
Max age
85 Years
Healthy volunteers
No
* Inclusion Criteria:
* Adults aged 19-85 years
* Undergoing colonoscopic polypectomy for colorectal adenoma
* Able to understand the study purpose and provide written informed consent
* Adequate tissue available for both adenoma and adjacent normal mucosa sampling
* Exclusion Criteria:
* History of colorectal cancer, inflammatory bowel disease, or hereditary colorectal cancer syndrome (e.g., FAP, Lynch syndrome)
* Previous colorectal surgery that may alter anatomy or pathology
* Inadequate sample quality or failure of DNA extraction
* Refusal or withdrawal of informed consent
* Severe comorbidities that make participation unsuitable at investigator's discretion
Primary outcome measure(s)
Methylation index of SFRP2 in colorectal tissue — Baseline (Single Time Point)] Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).
Methylation index of TFPI2 in colorectal tissue — Baseline (Single Time Point)] Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).
Methylation index of SEPT9 in colorectal tissue — Baseline (Single Time Point)] Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).
Methylation index of SDC2 in colorectal tissue — Baseline (Single Time Point)] Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.